Ep.3 What We're Watching at ASCO 2024
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Ep.3 What We're Watching at ASCO 2024
-
Narrated by:
-
Written by:
About this listen
As the Bluestar team prepares to head to ASCO 2024 this upcoming weekend, Bluestar Principal Jeff Fineberg sits down with Bluestar Managing Director Erin Olsen to talk about interesting abstracts related to two topics:
- What are the unmet needs in 1L therapy?
- The KRAS G12C mutation landscape
No reviews yet